FindTrial
Sign In

BTX-A51

DRUG3 trials

Sponsors

Edgewood Oncology Inc., Michael Wagner, MD

Conditions

Acute Myeloid LeukemiaAdvanced Solid TumorCIC-Rearranged SarcomaLiposarcomaMDM2 Gene AmplificationMetastatic Breast CancerMetastatic LiposarcomaMyelodysplastic Syndrome

Phase 1

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RecruitingNCT04243785
Edgewood Oncology Inc.Acute Myeloid Leukemia, Myelodysplastic Syndrome
Start: 2020-01-06End: 2027-03-31Target: 80Updated: 2024-03-20
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RecruitingNCT04872166
Edgewood Oncology Inc.Advanced Solid Tumor, Metastatic Breast Cancer
Start: 2021-06-07End: 2027-05-31Target: 112Updated: 2025-01-30
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
Active, not recruitingNCT06414434
Michael Wagner, MDCIC-Rearranged Sarcoma, Liposarcoma, MDM2 Gene Amplification +4
Start: 2024-09-30End: 2027-06-01Target: 24Updated: 2026-07-01

Related Papers

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.
2025-07-151 citations
Abstract P2-10-27: An Open Label Study of BTX-A51 in Patients with ER+/HER2- GATA3 Mutant and Wild Type Metastatic Breast Cancer
Clinical Cancer Research2025-06-13
Abstract 2980: Therapeutic potential of combined targeting of casein kinase 1 alpha (CK1 alpha) and CDK7/9 with the inhibitor BTX-A51 in human liposarcomas
Cancer Research2025-04-21
A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations
Blood2022-11-15
Safety and efficacy of casein kinase 1α and cyclin dependent kinase 7/9 inhibition in patients with relapsed or refractory AML: A first-in-human study of BTX-A51.
Journal of Clinical Oncology2022-06-014 citations
Trial in Progress: A Phase I Trial of BTX-A51 in Patients with Relapsed or Refractory AML or High-Risk MDS
Blood2020-11-046 citations